Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Ulevostinag |
Synonyms | |
Therapy Description |
Ulevostinag (MK-1454) is an agonist of the stimulator of interferon genes protein (TMEM173, STING1), that when activated leads to the release of cytokines that stimulate cytotoxic T lymphocytes to enhance the anti-tumor immune response (Ann Oncol, Oct 2018, 29 (suppl 8), abstract LBA15, PMID: 31355488). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Ulevostinag | MK 1454|MK-1454 | STING1 Agonist 19 | Ulevostinag (MK-1454) is an agonist of the stimulator of interferon genes protein (TMEM173, STING1), that when activated leads to the release of cytokines that stimulate cytotoxic T lymphocytes to enhance the anti-tumor immune response (Ann Oncol, Oct 2018, 29 (suppl 8), abstract LBA15, PMID: 31355488). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03010176 | Phase I | Pembrolizumab + Ulevostinag Ulevostinag | Study of MK-1454 Alone or in Combination With Pembrolizumab in Participants With Advanced/Metastatic Solid Tumors or Lymphomas (MK-1454-001) | Completed | USA | ISR | GBR | FRA | 1 |